Curis (NASDAQ:CRIS – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($1.36) per share and revenue of $2.04 million for the quarter.
Curis Stock Down 0.3 %
NASDAQ:CRIS opened at $3.01 on Wednesday. The stock’s 50 day moving average price is $3.30 and its 200 day moving average price is $4.28. The company has a market capitalization of $25.49 million, a PE ratio of -0.39 and a beta of 3.41. Curis has a 52-week low of $2.86 and a 52-week high of $17.49.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Curis in a research note on Tuesday, December 10th.
Curis Company Profile
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
See Also
- Five stocks we like better than Curis
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- What is the S&P/TSX Index?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
